

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Palopegteriparatide for treating chronic hypoparathyroidism ID6380**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Ascendis Pharma (palopegteriparatide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Amend</li> <li>• Butterfly Thyroid Cancer Trust</li> <li>• British Thyroid Foundation</li> <li>• Kidney Care UK</li> <li>• National Kidney Federation</li> <li>• Parathyroid UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thyroid UK</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Endocrine and Thyroid Surgeons</li> <li>• British Association of Surgical Oncology</li> <li>• British Geriatrics Society</li> <li>• British Society for Haematology</li> <li>• British Thyroid Association</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Endocrinology</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Kidney Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AAH Pharmaceuticals (alfacalcidol, calcitriol, calcium carbonate, calcium gluconate, teriparatide)</li> <li>• Accord Healthcare UK (calcium carbonate, calcium gluconate)</li> <li>• Alliance Healthcare (alfacalcidol, calcitriol)</li> <li>• Atnahs Pharma UK (calcitriol, chlortalidone, hydrochlorothiazide)</li> <li>• Aurobindo Pharma (hydrochlorothiazide)</li> <li>• B.Braun Medical (calcium gluconate)</li> <li>• Boehringer Ingelheim (hydrochlorothiazide)</li> <li>• Brown &amp; Burk UK (hydrochlorothiazide)</li> <li>• Crescent Pharma (alfacalcidol)</li> </ul>

Final stakeholder list for the evaluation of palopegteriparatide for treating chronic hypoparathyroidism ID6380

Issue date: September 2024

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Daiichi Sankyo UK (hydrochlorothiazide)</li> <li>• Eli Lilly (teriparatide)</li> <li>• Essential Healthcare (alfacalcidol, calcium carbonate)</li> <li>• Forum Health Products (calcium carbonate)</li> <li>• Galderma UK (calcitriol)</li> <li>• Galen (calcium carbonate)</li> <li>• Gedeon Richter UK (teriparatide)</li> <li>• Glenmark Pharmaceuticals (hydrochlorothiazide)</li> <li>• Grunenthal (calcium carbonate)</li> <li>• Haleon UK (calcium carbonate)</li> <li>• HealthAid (calcium carbonate)</li> <li>• Hameln Pharma (calcium gluconate)</li> <li>• Internis Pharmaceuticals (calcium carbonate)</li> <li>• Mylan (calcium carbonate, hydrochlorothiazide)</li> <li>• Kyowa Kirin (calcium carbonate)</li> <li>• Medihealth Northern (alfacalcidol, calcitriol, chlortalidone)</li> <li>• Mylan (bendroflumethiazide, indapamide)</li> <li>• Morningside Healthcare (chlortalidone)</li> <li>• Neon Healthcare (alfacalcidol, calcium carbonate)</li> <li>• Novartis Pharmaceuticals (hydrochlorothiazide)</li> <li>• Organon Pharma UK (hydrochlorothiazide)</li> <li>• Pfizer (hydrochlorothiazide)</li> <li>• Phoenix Healthcare Distribution (alfacalcidol, calcitriol, calcium carbonate)</li> <li>• Ranbaxy UK (teriparatide)</li> <li>• Roche Products (calcitriol)</li> <li>• Sandoz (calcium carbonate)</li> <li>• Sanofi (hydrochlorothiazide)</li> <li>• Sigma Pharmaceuticals (alfacalcidol, bendroflumethiazide, calcitriol, chlortalidone, hydrochlorothiazide, indapamide)</li> <li>• Stirling Anglian Pharmaceuticals (calcium carbonate)</li> </ul>

Final stakeholder list for the evaluation of palopepteriparatide for treating chronic hypoparathyroidism ID6380

Issue date: September 2024

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• Strides Pharma (alfacalcidol)</li> <li>• Takeda UK (calcium carbonate, recombinant human parathyroid hormone)</li> <li>• Teva UK (calcitriol, teriparatide)</li> <li>• Theramex (alfacalcidol)</li> <li>• Thornton and Ross (teriparatide, hydrochlorothiazide)</li> <li>• TriOn Pharma (alfacalcidol, calcium carbonate)</li> <li>• Wockhardt UK (chlortalidone, hydrochlorothiazide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>• Cochrane Haematology</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.